Trevor Robey, INC. — Client Intake

// 01 — WHAT DO YOU NEED?

De-risk a specific asset

Investor Pre-Mortem · $9,950 / $14,950 / $19,950

Per-asset risk dossier: trial design, comparable failures, IP runway. Every claim PMID/NCT/ChEMBL-traced.

Why did programs fail in this space?

Failed Trial Archaeology · $14,950

Structured post-mortem of Phase 2/3 terminations in a mechanism or indication. NCT-indexed failure pattern matrix with sponsor stop reasons.

Safety signal or adverse event review

Pharmacovigilance Pack · $2,500–$4,950

FAERS, DailyMed, RxNorm scan at runtime. Reproducibility manifest included; every signal entry carries a source identifier.

Validate or score a target

Cross-Silo Connector Report · $9,950–$24,950

OpenTargets, UniProt, HPA, InterPro — four orthogonal evidence streams. PPI network mapping included.

Rare disease landscape

Rare Disease Brief / Plain-Language Patient Brief · $2,500+

Orphan drug pipeline, genetic basis, OMIM/OrphaNet intelligence. Plain-language patient brief at 8th-grade health-literacy level available.

General biomedical research question

General Research Pack · Quoted on request

Topic not fitting the above categories — scope and pricing discussed directly.

// 02 — BIOMEDICAL ENTITY

Select an engagement type above to see the relevant entity fields.

COMPOUND / ASSET NAME

Used to query ChEMBL, PubMed, and ClinicalTrials.gov at runtime

INDICATION / TARGET DISEASE

Scopes the trial landscape and comparable failure set

THERAPEUTIC AREA

Scopes the failed-trial corpus in ClinicalTrials.gov

CLINICAL TRIAL PHASE (OPTIONAL)

Limits ClinicalTrials.gov stop-reason query to this phase

DRUG CLASS OR COMPOUND

Used to scope FAERS and DailyMed safety queries

TARGET GENE / PROTEIN

Queried across OpenTargets, UniProt, HPA, and InterPro

DISEASE CONTEXT (OPTIONAL)

Narrows OpenTargets genetic association filter

RARE DISEASE NAME OR OMIM ID

Queried against OMIM, OrphaNet, and ClinicalTrials.gov

FOCUS AREA (OPTIONAL)

Focuses synthesis scope

RESEARCH TOPIC OR QUESTION

// 03 — SCOPE

DESIRED TURNAROUND

▾

ADDITIONAL CONTEXT OR CONSTRAINTS

// 04 — CONTACT

FULL NAME ORGANIZATION EMAIL ROLE / TITLE (OPTIONAL)

Helps route to the right SKU tier

This opens your email client with all fields pre-filled. No data is transmitted to any server.

Citation-Audit SLA — refund-backed.

GROUNDED-CITATION GATE — WHAT SHIPS AND WHAT DOESN'T

Every cited identifier (PMID, NCT, ChEMBL CID, DOI) is cross-checked against the union of identifiers actually returned by live database tool calls during the same run — not model memory. If the grounded-citation ratio falls below the configured threshold, the report hard-fails PHASE30_CITATION_UNVERIFIED and does not ship.

Cited DOIs are screened against Crossref's retraction record before delivery. A report citing any confirmed retracted paper hard-stops PHASE30_CITATION_RETRACTED. The screen is fail-soft: a Crossref network error yields checked:false and does not wrongly block a passing report.

Retraction screening applies to cited DOIs only — PMIDs and NCTs are not routed through Crossref.

Every claim, sourced. Every risk, named. In days, not weeks.

SPEED & COST — WHAT THE NUMBERS ACTUALLY SAY

· Investor Pre-Mortem: written 5–10 business day Speed SLA — $9,950 / $14,950 / $19,950 · Conference Synthesis Brief: 24–48 hours (500+ ASCO/ESMO/AACR abstracts synthesized) — $4,950 · Failed Trial Archaeology: days, not weeks — $14,950 · Pharmacovigilance Pack — $2,500–$4,950 · Cross-Silo Connector Report — $9,950–$24,950 · Other SKUs: timeline confirmed at intake; no written Speed SLA outside Investor Pre-Mortem

McKinsey runs 2–6 weeks at $150K–$750K. We run a fifth of the time at a tenth of the price.

The 5–10 business day Speed SLA applies to Investor Pre-Mortem deliveries only. Conference Synthesis Brief 24–48 hr claim is SKU-specific (OFFERINGS.md). The McKinsey comparison is sourced from the internal revenue playbook — not independently verified. Timelines for other SKUs are confirmed at intake.

Grade	Grounded ratio	Meaning
A	≥ 90%	All major claims traceable to retrieved records
B	75–89%	Solid provenance; minor unverified cites annotated
C	50–74%	Acceptable; unverified cites flagged [UNVERIFIED]
D	< 50%	Many citations not grounded in fetched evidence
F / BLOCKED	any retraction	Retracted DOI cited — delivery blocked

WHAT YOU RECEIVE — SEALED, AUDITABLE BUNDLE

· Full research report with inline [UNVERIFIED] annotations on any citation not grounded in runtime-fetched records · citation-integrity.md — A–F graded provenance ledger · graveyard-memo.md — NCT-traced failure archaeology (indication-scoped reports) · reproducibility-manifest.json — per-identifier resolution record with HTTP status and resolved URL · checksums.txt + manifest.json — SHA-256 seals on all deliverable files · Delivered as a ZIP via secure email; enterprise handoff to Snowflake, AWS Data Exchange, or BigQuery available · Citation-Audit SLA — refund-backed